417
Views
1
CrossRef citations to date
0
Altmetric
Review

Idiopathic Pulmonary Fibrosis: What do we Know about the Role of Occupational and Environmental Determinants? A Systematic Literature Review and Meta-Analysis

, , , , ORCID Icon, & show all

References

  • Abramson, M. J., S. M. Tsitsi Murambadoro, G. P. Alif, S. C. Benke, I. G. Dharmage, R. F. Peter Hopkins, S. K. Hoy, Y. Moodley, P. N. Shuli Rawson, R. W. Reynolds, et al. 2020. Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: Case-control study. Thorax 75:864–69. doi:10.1136/thoraxjnl-2019-214478.
  • American Thoracic Society. 2000. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 161: 646–64. doi:10.1164/ajrccm.161.2.ats3-00.
  • Andersson, M., P. D. Blanc, K. Toren, and B. Jarvholm. 2021. Smoking, occupational exposures, and idiopathic pulmonary fibrosis among Swedish construction workers. Am. J. Indust. Med. 64:251–57. doi:10.1002/ajim.23231.
  • Asif, M. 2009. Sustainability of construction materials: Part 2: Sutainability of timber, wood and bamboo in construction. In Woodhead Publishing Series in Civil and Structural Engineering, 31–54. doi:10.1533/9781845695842.31.
  • Awadalla, N. J., A. Hegazy, R. A. Elmetwally, and I. Wahby. 2012. Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Egypt: A multicenter case-control study. Int J Occup Environ Med 3 (3):107–16.
  • Baumgartner, K. B., J. M. Samet, D. B. Coultas, C. A. Stidley, W. C. Hunt, T. V. Colby, and J. A. Waldron. 2000. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: A multicenter case-control study. Collaborating Centers. Am. J. Epidemiol. 152:307–15. doi:10.1093/aje/152.4.307.
  • Bellou, V., L. Belbasis, and E. Evangelou. 2021. Tobacco smoking and risk for pulmonary fibrosis: A prospective cohort study from the UK biobank. Chest 160 (3):983–93. doi:10.1016/j.chest.2021.04.035.
  • Blanc, P. D., I. Annesi-Maesano, J. R. Balmes, K. J. Cummings, D. Fishwick, D. Miedinger, N. Murgia, R. N. Naidoo, C. J. Reynolds, T. Sigsgaard, et al. 2019. The occupational burden of onmalignant respiratory diseases. An official American Thoracic Society and European Respiratory Society Statement. Am. J. Respir. Crit. Care Med. 199 (11):1312–34. doi:10.1164/rccm.201904-0717ST.
  • Blangiardo, M., M. Pirani, L. Kanapka, A. Hansell, and G. Fuller. 2019. A hierarchical modelling approach to assess multi pollutant effects in time-series studies. PLoS One 14:e0212565. doi:10.1371/journal.pone.0212565.
  • Bornholdt, J., A. T. Saber, A. K. Sharma, K. Savolainen, U. Vogel, and H. Wallin. 2007. Inflammatory response and genotoxicity of seven wood dusts in the human epithelial cell line A549. Mut. Res. 632 (1–2):78–88. doi:10.1016/j.mrgentox.2007.04.016.
  • Bourke, S. C., and H. Clague. 2000. Review of cryptogenic fibrosing alveolitis, including current treatment guidelines. Postgrad. Med. J. 76 (900):618–24. doi:10.1136/pmj.76.900.618.
  • Canestaro, W. J., S. H. Forrester, G. Raghu, L. Ho, and B. E. Devine. 2016. Drug treatment of idiopathic pulmonary fibrosis: Systematic review and network meta-analysis. Chest 149 (3):756–66. doi:10.1016/j.chest.2015.11.013.
  • Chauvin, P., M. Kerjouan, P. Jego, S. Jouneau, and A. Lescoat. 2021. [Hypersensitivity Pneumonitis: An update]. Rev. Med. Interne 42 (11):772–80. doi:10.1016/j.revmed.2021.03.333.
  • Cottin, V., N. A. Hirani, D. L. Hotchkin, A. M. Nambiar, T. Ogura, M. Otaola, D. Skowasch, J. S. Park, H. K. Poonyagariyagorn, W. Wuyts, et al. 2018. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 27.
  • Cottin, V., L. Wollin, A. Fischer, M. Quaresma, S. Stowasser, and S. Harari. 2019. Fibrosing interstitial lung diseases: Knowns and unknowns. Eur. Respir. Rev. 28.
  • Demers, P. A., K. Teschke, and S. M. Kennedy. 1997. What to do about softwood? A review of respiratory effects and recommendations regarding exposure limits. Am. J. Ind. Med. 31 (4):385–98. doi:10.1002/(SICI)1097-0274(199704)31:4<385::AID-AJIM3>3.0.CO;2-V.
  • Dominici, F., R. D. Peng, C. D. Barr, and M. L. Bell. 2010. Protecting human health from air pollution: Shifting from a single-pollutant to a multipollutant approach. Epidemiology 21 (2):187–94. doi:10.1097/EDE.0b013e3181cc86e8.
  • Ekstrom, M., T. Gustafson, K. Boman, K. Nilsson, G. Tornling, N. Murgia, and K. Toren. 2014. Effects of smoking, gender and occupational exposure on the risk of severe pulmonary fibrosis: A population-based case-control study. BMJ Open 4 (1):e004018. doi:10.1136/bmjopen-2013-004018.
  • Garcia-Sancho Figueroa, M. C., G. Carrillo, R. Perez-Padilla, M. R. Fernandez-Plata, I. Buendia-Roldan, M. H. Vargas, and M. Selman. 2010. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. Respir. Med. 104 (2):305–09. doi:10.1016/j.rmed.2009.08.013.
  • George, P. M., P. Spagnolo, M. Kreuter, G. Altinisik, M. Bonifazi, F. J. Martinez, P. L. Molyneaux, E. A. Renzoni, L. Richeldi, S. Tomassetti, et al.; I. L. D. working group Erice. 2020. Progressive fibrosing interstitial lung disease: Clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir. Med. 8 (9):925–34. doi:10.1016/S2213-2600(20)30355-6.
  • Glass, D. S., D. Grossfeld, H. A. Renna, P. Agarwala, P. Spiegler, J. DeLeon, and A. B. Reiss. 2022. Idiopathic pulmonary fibrosis: Current and future treatment. Clin Respir J 16 (2):84–96. doi:10.1111/crj.13466.
  • Glass, D. S., D. Grossfeld, H. A. Renna, P. Agarwala, P. Spiegler, L. J. Kasselman, A. D. Glass, J. DeLeon, and A. B. Reiss. 2020. Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches. Respir. Investig. 58 (5):320–35. doi:10.1016/j.resinv.2020.04.002.
  • Gustafson, T., A. Dahlman-Hoglund, K. Nilsson, K. Strom, G. Tornling, and K. Toren. 2007. Occupational exposure and severe pulmonary fibrosis. Respir. Med. 101 (10):2207–12. doi:10.1016/j.rmed.2007.02.027.
  • Hancock, D. G., M. E. Langley, K. L. Chia, R. J. Woodman, and E. M. Shanahan. 2015. Wood dust exposure and lung cancer risk: A meta-analysis. Occup. Environ. Med. 72 (12):889–98. doi:10.1136/oemed-2014-102722.
  • Harris, J. M., P. Cullinan, and J. C. McDonald. 2001. Occupational distribution and geographic clustering of deaths certified to be cryptogenic fibrosing alveolitis in England and wales. Chest 119 (2):428–33. doi:10.1378/chest.119.2.428.
  • Hubbard, R., M. Cooper, M. Antoniak, A. Venn, S. Khan, I. Johnston, S. Lewis, and J. Britton. 2000. Risk of cryptogenic fibrosing alveolitis in metal workers. Lancet 355 (9202):466–67. doi:10.1016/S0140-6736(00)82017-6.
  • Hubbard, R., S. Lewis, K. Richards, I. Johnston, and J. Britton. 1996. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 347 (8997):284–89. doi:10.1016/S0140-6736(96)90465-1.
  • Iwai, K., T. Mori, N. Yamada, M. Yamaguchi, and Y. Hosoda. 1994. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am. J. Respir. Crit. Care Med. 150 (3):670–75. doi:10.1164/ajrccm.150.3.8087336.
  • Kim, S. Y., D. M. Kang, H. K. Lee, K. H. Kim, and J. Choi. 2017. Occupational and environmental risk actors for chronic fibrosing idiopathic interstitial pneumonia in South Korea. J. Occup. Environ. Med. 59 (11):e221–e226. doi:10.1097/JOM.0000000000001153.
  • Koo, J. W., J. P. Myong, H. K. Yoon, C. K. Rhee, Y. Kim, J. S. Kim, B. S. Jo, Y. Cho, J. Byun, M. Choi, et al. 2017. Occupational exposure and idiopathic pulmonary fibrosis: A multicentre case-control study in Korea. Int. J. Tuberc. Lung Dis. 21 (1):107–12. doi:10.5588/ijtld.16.0167.
  • Lee, C. T., and K. A. Johannson. 2020. Occupational exposures and IPF: When the dust unsettles. Thorax 75 (10):828–29. doi:10.1136/thoraxjnl-2020-215567.
  • Lee, S. H., D. S. Kim, Y. W. Kim, M. P. Chung, S. T. Uh, C. S. Park, S. H. Jeong, Y. B. Park, H. L. Lee, J. S. Song, et al. 2015. Association between occupational dust exposure and prognosis of idiopathic pulmonary fibrosis: A Korean national survey. Chest 147 (2):465–74. doi:10.1378/chest.14-0994.
  • Lynch, J. P., 3rd, R. H. Huynh, M. C. Fishbein, R. Saggar, J. A. Belperio, and S. S. Weigt. 2016. Idiopathic pulmonary fibrosis: Epidemiology, clinical features, prognosis, and management. Semin. Respir. Crit. Care. Med 37 (3):331–57. doi:10.1055/s-0036-1582011.
  • Maatta, J., R. Luukkonen, K. Husgafvel-Pursiainen, H. Alenius, and K. Savolainen. 2006. Comparison of hardwood and softwood dust-induced expression of cytokines and chemokines in mouse macrophage RAW 264.7 cells. Toxicology 218 (1):13–21. doi:10.1016/j.tox.2005.09.001.
  • Majewski, S., and W. J. Piotrowski. 2020. Air pollution-An overlooked risk factor for idiopathic pulmonary fibrosis. J Clin Med 10.
  • Meyer, K. C. 2017. Pulmonary fibrosis, part I: Epidemiology, pathogenesis, and diagnosis. Expert Rev Respir Med 11 (5):343–59. doi:10.1080/17476348.2017.1312346.
  • Miyake, Y., S. Sasaki, T. Yokoyama, K. Chida, A. Azuma, T. Suda, S. Kudoh, N. Sakamoto, K. Okamoto, G. Kobashi, et al. 2005. Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan. Ann. Occup. Hyg. 49 (3):259–65. doi:10.1093/annhyg/meh090.
  • Moher, D., A. Liberati, J. Tetzlaff, D. G. Altman, and P. Group. 2009. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Br. Med. J. 339:b2535. doi:10.1136/bmj.b2535.
  • Morell, F., A. Villar, M. A. Montero, X. Munoz, T. V. Colby, S. Pipvath, M. J. Cruz, and G. Raghu. 2013. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: A prospective case-cohort study. Lancet Respir. Med. 1 (9):685–94. doi:10.1016/S2213-2600(13)70191-7.
  • Mossman, B. T., and A. Churg. 1998. Mechanisms in the pathogenesis of asbestosis and silicosis. Am. J. Respir. Crit. Care Med. 157 (5):1666–80. doi:10.1164/ajrccm.157.5.9707141.
  • Moss, B. J., S. W. Ryter, and I. O. Rosas. 2022. Pathogenic mechanisms underlying idiopathic pulmonary fibrosis. Annu. Rev. Pathol. 17:515–46. doi:10.1146/annurev-pathol-042320-030240.
  • Nalysnyk, L., J. Cid-Ruzafa, P. Rotella, and D. Esser. 2012. Incidence and prevalence of idiopathic pulmonary fibrosis: Review of the literature. Eur. Respir. Rev. 21 (126):355–61. doi:10.1183/09059180.00002512.
  • Oda, K., K. Yatera, Y. Fujino, H. Ishimoto, H. Nakao, T. Hanaka, T. Ogoshi, T. Kido, K. Fushimi, S. Matsuda, et al. 2016. Efficacy of concurrent treatments in idiopathic pulmonary fibrosis patients with a rapid progression of respiratory failure: An analysis of a national administrative database in Japan. BMC Pulm. Med. 16 (1):91. doi:10.1186/s12890-016-0253-x.
  • Oda, K., K. Yatera, Y. Fujino, T. Kido, T. Hanaka, K. Sennari, K. Fushimi, S. Matsuda, and H. Mukae. 2018. Respiratory comorbidities and risk of mortality in hospitalized patients with idiopathic pulmonary fibrosis. Respir. Investig. 56 (6):4–71. doi:10.1016/j.resinv.2017.09.006.
  • Ojima, J. 2016. Generation rate and particle size distribution of wood dust by handheld sanding operation. J. Occup. Health 58 (6):640–43. doi:10.1539/joh.16-0136-BR.
  • Olson, A. L., A. H. Gifford, N. Inase, E. R. Fernandez Perez, and T. Suda. 2018. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur. Respir. Rev. 27.
  • Paolocci, G., I. Folletti, K. Toren, M. Ekstrom, M. Dell’Omo, G. Muzi, and N. Murgia. 2018. Occupational risk factors for idiopathic pulmonary fibrosis in Southern Europe: A case-control study. BMC Pulm. Med. 18 (1):75. doi:10.1186/s12890-018-0644-2.
  • Park, Y., C. Ahn, and T. H. Kim. 2021. Occupational and environmental risk factors of idiopathic pulmonary fibrosis: A systematic review and meta-analyses. Sci. Rep. 11 (1):4318. doi:10.1038/s41598-021-81591-z.
  • Park, Y., C. Ahn, and T.-H. Kim. 2021. Occupational and environmental risk factors of idiopathic pulmonary fibrosis: A systematic review and meta-analyses. Sci Rep, 11:4313.
  • Pędzik, M., K. Stuper-Szablewska, M. Sydor, and T. Rogoziński. 2020. Influence of grit size and wood species on the granularity of dust particles during sanding. Appl. Sci. 10 (22):8165. doi:10.3390/app10228165.
  • Phan, T. H. G., P. Paliogiannis, G. K. Nasrallah, R. Giordo, A. H. Eid, A. G. Fois, A. Zinellu, A. A. Mangoni, and G. Pintus. 2021. Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis. Cell. Mol. Life Sci. 78 (5):2031–57. doi:10.1007/s00018-020-03693-7.
  • Pinheiro, G. A., V. C. Antao, J. M. Wood, and J. T. Wassell. 2008. Occupational risks for idiopathic pulmonary fibrosis mortality in the United States. Int. J. Occup. Environ. Health. 14 (2):117–23. doi:10.1179/oeh.2008.14.2.117.
  • Pylkkanen, L., H. Stockmann-Juvala, H. Alenius, K. Husgafvel-Pursiainen, and K. Savolainen. 2009. Wood dusts induce the production of reactive oxygen species and caspase-3 activity in human bronchial epithelial cells. Toxicology 262 (3):265–70. doi:10.1016/j.tox.2009.06.019.
  • Raghu, G., M. Remy-Jardin, J. L. Myers, L. Richeldi, C. J. Ryerson, D. J. Lederer, J. Behr, V. Cottin, S. K. Danoff, F. Morell, et al.; European Respiratory Society Japanese Respiratory Society American Thoracic Society, and Society Latin American Thoracic. 2018. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 198 (5):e44–e68. doi:10.1164/rccm.201807-1255ST.
  • Rivera-Ortega, P., and M. Molina-Molina. 2019. Interstitial lung diseases in developing countries. Ann. Glob. Health 85 (1):85. doi:10.5334/aogh.2352.
  • Russell, A. M., E. Ripamonti, and C. Vancheri. 2016. Qualitative European survey of patients with idiopathic pulmonary fibrosis: Patients’ perspectives of the disease and treatment. BMC Pulm. Med. 16 (1):10. doi:10.1186/s12890-016-0171-y.
  • Scott, J., I. Johnston, and J. Britton. 1990. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. Br. Med. J. 301 (6759):1015–57. doi:10.1136/bmj.301.6759.1015.
  • Somogyi, V., N. Chaudhuri, S. E. Torrisi, N. Kahm, V. Muller, and M. Kreuter. 2018. The therapy of idiopathic pulmonary fibrosis: What is next? Eur. Respir. Rev. 28 (153):190021. doi:10.1183/16000617.0021-2019.
  • Spagnolo, P., N. Sverzellati, G. Rossi, A. Cavazza, A. Tzouvelekis, B. Crestani, and C. Vancheri. 2015. Idiopathic pulmonary fibrosis: A update. Ann. Med. 47 (1):15–27. doi:10.3109/07853890.2014.982165.
  • Stroup, D. F., J. A. Berlin, S. C. Morton, I. Olkin, G. D. Williamson, D. Rennie, D. Moher, B. J. Becker, T. A. Sipe, and S. B. Thacker. 2000. Meta-analysis of Observational Studies in Epidemiology A Proposal for Reporting. J. Am. Med. Assoc. 283 (15):2008–12. doi:10.1001/jama.283.15.2008.
  • Taskar, V. S., and D. B. Coultas. 2006. Is idiopathic pulmonary fibrosis an environmental disease? Proc. Am. Thorac. Soc. 3 (4):293–98. doi:10.1513/pats.200512-131TK.
  • Trethewey, S. P., and G. I. Walters. 2018. The role of occupational and environmental exposures in the pathogenesis of idiopathic pulmonary fibrosis: A narrative literature review. Medicina (Kaunas) 54.
  • Tzouvelekis, A., F. Bonella, and P. Spagnolo. 2015. Update on therapeutic management of idiopathic pulmonary fibrosis. Ther. Clin. Risk. Manag. 11:359–70. doi:10.2147/TCRM.S69716.
  • van Manen, M. J., S. S. Birring, C. Vancheri, V. Cottin, E. A. Renzoni, A. M. Russell, and M. S. Wijsenbeek. 2016. Cough in idiopathic pulmonary fibrosis. Eur. Respir. Rev. 25 (141):278–86. doi:10.1183/16000617.0090-2015.
  • Veroniki, A. A., D. Jackson, W. Viechtbauer, R. Bender, J. Bowden, G. Knapp, O. Kuss, J. P. Higgins, D. Langan, and G. Salanti. 2016. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res. Synth. Meth. 7 (1):55–79. doi:10.1002/jrsm.1164.
  • Walters, G. I. 2020. Occupational exposures and idiopathic pulmonary fibrosis. Curr. Opin. Allergy Clin. Immunol. 20 (2):103–11. doi:10.1097/ACI.0000000000000610.
  • Wells, G. A., B. Shea, D. O’Connell, J. Peterson, V. Welch, M. Losos. 2016. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.